|
T.TH
|
My investment theory for Thera before the bad news in oncology was based on...
|
|
T.TH
|
One way that would allow to restart the phase I on TH1902 is to forget the...
|
|
T.TH
|
Pushing in NASH an obesity needs the means of a big pharma and youneed...
|
|
T.TH
|
Egrifta (tesamorelin) an analog of GRF (1-44) could be very efficacious a fat...
|
|
T.TH
|
You need biopsies of the real tumors, and even biopsies are not good enough...
|
|
T.TH
|
I wrote here, well before the news about pausing the clinical trial, that...
|
|
T.TH
|
The analysis of the TH1902 program is quite easy to make, unless they have...
|
|
T.TH
|
That's why they ideally need a partner. The other day I listened to a...
|
|
T.TH
|
I was obviously talking about an hypothetical Ga68-DOTA-TH19P01 imaging PDC...
|
|
T.TH
|
With the actual situation I flushed my ignore list to get as many point of...
|
|
T.TH
|
I will repeat myself for maybe the tenth time about that, but the ressources...
|
|
T.TH
|
Sorry, if lower and more frequent doses bring more TH1902 into cells...
|
|
T.TH
|
There you have it. I am repeating that docetaxel is not good enough as a...
|
|
T.TH
|
This was an obvious fraud since a long while for anybody with two onces of...
|
|
T.TH
|
We all complain about very poor communication, rightly so, but the bottom...
|
|
T.TH
|
What I mean is that the way they came out led the market to count TH1902 as...
|
|
T.TH
|
The thing is that I think the SP would not have gone much lower if they would...
|
|
T.TH
|
I don't know how this story will end up, but one thing is sure, small...
|
|
T.TH
|
As 2022 draws to a close, we are excited to celebrate the strength of our...
|
|
T.TH
|
Those who wanted a promotional CEO, Andre DeVillers, who was also the founder...
|